CD40 Specific Neutra™ Antibody Products
Product listThe CD40 molecule (CD40) is a member of the TNF-receptor superfamily, which is also known as TNFRSF5, p50, and CD40L receptor. CD40 is the receptor for TNFSF5/CD40LG, which is primarily expressed on activated CD4+ T cells. Isoform I of CD40 is a single pass type I membrane protein while isoform II is secreted outside the cells. CD40 is overexpressed in normal peripheral blood mononuclear cells, breast, platelets, and gallbladder. CD40 deficiency may lead to diseases such as immunodeficiency with hyper-IgM type 3 (HIGM3), inflammatory diseases, and atherothrombosis.
Its Gene ID: 958, UniProtKB ID: P25942, and OMIM ID: 109535.
Functions of CD40 Activation
The activated CD40 can transduce a lot of signal pathways and trigger various downstream effects of humoral and cellular immunity, as shown in Figure 1.
- Canonical and noncanonical NF-κB pathway
- MAP kinase pathway
- PI3K pathway
- phospholipase-Cγ signaling pathway
- JAK3-STAT5 pathway
Fig.1 Functions and signal pathways of CD40 in different immune cell types.1
Treatment Strategies Associated with CD40
CD40 is of great value in recruiting the immune system for effective and safe cancer immunotherapy. Treatment strategies for CD40 are listed below (Figure 2):
- Development of CD40 agonists as adjuvants for vaccines.
- Construction of Fc-engineered antibody to CD40 with enhanced cross-linking to antigen-presenting cells.
- Construction of bispecific antibodies targeting both CD40 and tumor-associated antigens (TAA).
- Combination with other treatments such as chemotherapy and immune checkpoint inhibition.
- CD40L+ CAR T cells in cellular therapy with enhanced recruitment and activation of immune effectors.
Fig.2 Next generation strategies of anti-CD40 agonistic antibodies.2
Clinical Significance of CD40
Table 1 provides a varied format list of CD40-based biological agents for the disease treatment.
Tab. 1 Candidate drugs associated with CD40.1
Creative Biolabs offers more than two hundred anti-CD40 antibody products for nearly twenty applications such as stimulation, agonist, and blocking. These antibody products with high affinity are subjected to strict quality control before release.
REFERENCES
- Bullock, Timothy NJ. "CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies." Cellular & molecular immunology 19.1 (2022): 14-22.
- Salomon, et al. "Next generation CD40 agonistic antibodies for cancer immunotherapy." Frontiers in Immunology 13 (2022): 940674.
